Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
After Mylan CEO Heather Bresch blamed the pharmaceutical "middlemen" for causing the high price of EpiPens in an interview Thursday, Steve Miller, MD, CMO of Express Scripts, countered that her statement couldn't be "farther from the truth," reported CNBC.
Heather Bresch, the Mylan CEO at the center of the EpiPen pricing controversy, addressed scrutiny over the Canonsburg, Pa.-based company's pricing practices in a televised interview Thursday on CNBC.
Sen. Joe Manchin (D-W.Va.) issued a statement Thursday regarding the high cost of EpiPens, reported ABC News. His daughter, Heather Bresch, is CEO of Mylan, the company behind the epinephrine injection.
Here are the five latest medical devices or drugs approved by the Food and Drug Administration.
Mylan is not the only drug company reaping financial benefits from excessive price hikes, reports USA Today.
The Food and Drug Administration recently approved a new post-dermal procedure product developed by Oculus Innovative Sciences.
The Food and Drug Administration rejected Amgen's new drug intended to treat hormonal imbalances that commonly occur in patients on dialysis, reports The Wall Street Journal.
"When contracting for physician preference items such as total joints, pacemakers, stents and other implants, it is wise to engage a group of physician stakeholders early on and involve them in the vendor selection process," said Rob Austin, director of…
The Food and Drug Administration approved Jubilant Life Sciences' new drug for the treatment of hypertension.
Starting in October, Greenville (S.C.) County School District will have to pay for EpiPens, which for the past three years were shipped to the district for free, according to a local NBC affiliate.